HOUSTON, Nov. 18, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a
biopharmaceutical company specializing in the development of novel
treatments for primary and metastatic cancers of the brain and
central nervous system, today announced that members of management
will participate in A.G.P.'s Virtual Healthcare Symposium on
Thursday, November 19th,
2020.
The event will consist of 1-on-1 virtual investor meetings.
Investors attending the conference virtually who are interested in
meeting with Company management should contact their A.G.P.
representative.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary
and metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
glioblastoma multiforme (GBM), an aggressive and incurable form of
brain cancer. CNS holds a worldwide exclusive license to the
Berubicin chemical compound and has acquired all data and know-how
from Reata Pharmaceuticals, Inc. related to a completed Phase 1
clinical trial with Berubicin in malignant brain tumors, which
Reata conducted in 2006. In this trial the overall response rate of
stable disease or better was 44%. This 44% disease control rate was
based on 11 patients (out of 25 evaluable patients) with stable
disease, plus responders. One patient experienced a durable
complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a
limited patient sample size and, while promising, are not a
guarantee that similar results will be achieved in subsequent
trials. By the end of 2020, CNS expects to commence a Phase 2
clinical trial of Berubicin for the treatment of GBM in the U.S.,
while a sub-licensee partner undertakes a Phase 2 trial in adults
and a first-ever Phase 1 trial in pediatric GBM patients in
Poland. Its second drug candidate,
WP1244, is a novel DNA binding agent that has shown in preclinical
studies that it is 500 times more potent than the chemotherapeutic
agent daunorubicin in inhibiting tumor cell proliferation.
For more information, please visit www.CNSPharma.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-agps-virtual-healthcare-symposium-301175686.html
SOURCE CNS Pharmaceuticals, Inc.